OmniAb (NASDAQ:OABI – Get Free Report) and Bio-Rad Laboratories (NYSE:BIO – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.
Institutional and Insider Ownership
72.1% of OmniAb shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for OmniAb and Bio-Rad Laboratories, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
| Bio-Rad Laboratories | 0 | 4 | 1 | 0 | 2.20 |
Earnings & Valuation
This table compares OmniAb and Bio-Rad Laboratories”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OmniAb | $18.67 million | 39.04 | -$64.78 million | ($0.34) | -14.81 |
| Bio-Rad Laboratories | $2.58 billion | 3.99 | $759.90 million | $37.97 | 10.14 |
Bio-Rad Laboratories has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares OmniAb and Bio-Rad Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | -108.11% | -16.74% | -14.79% |
| Bio-Rad Laboratories | 39.45% | 3.64% | 2.55% |
Risk and Volatility
OmniAb has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Summary
Bio-Rad Laboratories beats OmniAb on 9 of the 14 factors compared between the two stocks.
About OmniAb
OmniAb, Inc. is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases. The company’s technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
